Journal: EXCLI Journal

Article Title: A sulfated polysaccharide of Ecklonia cava inhibits the growth of colon cancer cells by inducing apoptosis

doi: 10.17179/excli2014-676

Figure Lengend Snippet: Effects of CPs against the growth inhibition in FM3A (A), B16F10 (B), and CT 26 (C and D) cells. The cells (0.5 × 10 4 cells/well) incubated with CPs (9.4, 18.8, 37.5, and/or 75.0 µg/mL) for 24 h, 48 h, and/or 72 h were used for MTT assay. The results are representative of three separate experiments (n = 3). Significance was expressed as *; P < 0.05 vs. non-treated control cells, †; P < 0.05 vs. ACP-treated cells, and ‡; P < 0.05 vs. AlCP-treated cells for 72 h.

Article Snippet: FM3A cell (mouse mammary carcinoma cell line) originated from the mammary gland of the C3H/He mouse was offered by Dr. Won-Suk Kim (BINEX Co., Ltd.).

Techniques: Inhibition, Incubation, MTT Assay, Control

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: The combination of C-REV and S-1 treatment leads to stronger regression of murine 4T1 tumor Fig. 1a: The in vitro sensitivity of 4T1 cells to C-REV with or without 5-FU was determined by MTT assays. Cells were infected with C-REV at various multiplicities of infection (MOIs). The results are shown as means ± SD. Fig. 1b and 1c: Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=8 per group) with equal average tumor volumes among both groups and both flanks. Fig. 1b, Treatment schema: the mice were treated with 10 mg/kg S-1 for 5 consecutive days per week for 2 weeks. C-REV was administered i.t. to mice on day 0, day 2, day 7, and day 9. Fig. 1c, C-REV was injected into the tumor on only one side (referred to as the injected side; the non-injected side is the contralateral side), and tumor sizes on both sides were measured twice a week. Fig. 1c: Tumor growth and Fig. 1d: mouse survival in 4T1 tumor models after treatment. For the evaluation of survival, death event was defined when the total tumor size reached 1500 mm 3 . ANOVA with a post-hoc Tukey test was performed for tumor size evaluation. Survival analysis was performed using the Kaplan–Meier method. The log-rank test was used for statistical comparison of the curves. * p < 0.05, * * p < 0.01, * * * p < 0.001

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: In Vitro, Infection, Injection, Comparison

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: Fractional cell survival (FCS) of 4T1 tumor cells following treatment with 5-FU and C-REV alone or in combination

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques:

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: C-REV enhances the infiltration of CD3 + CD8 + T cells into tumors and increases IFNγ production by CD3 + CD8 + T cells Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups with an equal average tumor volume among the groups and both flanks. Each group contained three mice. Mice were given S-1 (10 mg/kg) by oral gavage (5 consecutive days, day 0–4) in addition to an intratumoral injection of C-REV (5 × 10 5 PFU) on day 0 and day 2. Tumors were harvested 3 days after the final treatment from both the injected and non-injected sites. Fig. 2a: CD4 + T cells and Fig. 2b: CD8 + T cells, gated from CD45 + CD3 + cells after treatment with C-REV, S-1, and their combination, were analyzed by flow cytometry. Fig. 2c: Tumor-infiltrating lymphocytes were isolated. These cells were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: Injection, Flow Cytometry, Isolation, Staining

Journal: Nagoya Journal of Medical Science

Article Title: S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

doi: 10.18999/nagjms.83.4.683

Figure Lengend Snippet: C-REV enhances IFNγ production by CD3 + CD8 + T cells in tumor-draining lymph nodes Female 6- to 7-week-old Balb/c mice were inoculated with 4T1 tumor in the right and left flanks. When the average tumor volumes reached 100–200 mm 3 , mice were randomly divided into groups (n=3/group) with an equal average tumor volume among the groups and both flanks. Lymphocytes were harvested 3 days after the final treatment from tumor-draining lymph nodes. Fig. 5a: MDSC gated from CD45 + cells and Fig. 5b: T cells and those gated from CD45 + CD3 + cells were analyzed by flow cytometry after treatment with C-REV, S-1, and their combination. Fig. 5c: T cells isolated from tumor-draining lymph nodes were stimulated with anti-CD3/anti-CD28 antibody, and intracellular staining of IFNγ was performed. * p < 0.05, * * p < 0.01

Article Snippet: The murine breast cancer cell line 4T1 was obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Techniques: Flow Cytometry, Isolation, Staining